Nanos Medicare Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-12-2024
- Paid Up Capital ₹ 0.10 M
as on 16-12-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -61.58%
(FY 2022)
- Profit -955.47%
(FY 2022)
- Ebitda -177.61%
(FY 2022)
- Net Worth -681.24%
(FY 2022)
- Total Assets 10.89%
(FY 2022)
About Nanos Medicare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Maroof Khan, Saurabh Arora, and Javed Ali serve as directors at the Company.
- CIN/LLPIN
U52609DL2017PTC316820
- Company No.
316820
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nanos Medicare Private Limited offer?
Nanos Medicare Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Sexual Wellness Products, Erectile Dysfunction Medicine, Digestive System Drugs & Medicines, Antacid Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections.
Who are the key members and board of directors at Nanos Medicare?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Arora  | Director | 27-Apr-2017 | Current |
| Maroof Khan | Director | 27-Apr-2017 | Current |
| Javed Ali | Director | 27-Apr-2017 | Current |
Financial Performance of Nanos Medicare.
Nanos Medicare Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 61.58% decrease. The company also saw a substantial fall in profitability, with a 955.47% decrease in profit. The company's net worth observed a substantial decline by a decrease of 681.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nanos Medicare?
In 2022, Nanos Medicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nanos Medicare?
Nanos Medicare has a workforce of 7 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nanos Medicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nanos Medicare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
